Russell Investments Group
RPRX icon

Russell Investments Group’s Royalty Pharma RPRX Stock Holding History

Russell Investments Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.6M Buy
1,694,250
+296,292
+21% +$15.4M 0.08% 236
2026
Q1 		$66.8M Sell
1,397,958
-1,014
-0.1% -$44.4K 0.07% 276
2025
Q4 		$54.1M Sell
1,398,972
-6,941
-0.5% -$265K 0.06% 321
2025
Q3 		$49.6M Buy
1,405,913
+98,649
+8% +$3.57M 0.06% 348
2025
Q2 		$47.1M Sell
1,307,264
-286,493
-18% -$9.49M 0.06% 327
2025
Q1 		$49.6M Sell
1,593,757
-262,034
-14% -$8.31M 0.07% 296
2024
Q4 		$47.3M Buy
1,855,791
+449,551
+32% +$11.9M 0.07% 310
2024
Q3 		$39.8M Buy
1,406,240
+587,281
+72% +$16.3M 0.06% 344
2024
Q2 		$21.6M Buy
818,959
+416,816
+104% +$11.6M 0.03% 504
2024
Q1 		$12.2M Buy
402,143
+79,176
+25% +$2.33M 0.02% 740
2023
Q4 		$9.05M Buy
322,967
+54,907
+20% +$1.51M 0.02% 835
2023
Q3 		$7.23M Sell
268,060
-38,140
-12% -$1.13M 0.01% 905
2023
Q2 		$9.39M Sell
306,200
-120,408
-28% -$4.08M 0.02% 806
2023
Q1 		$15.4M Buy
426,608
+45,157
+12% +$1.67M 0.03% 605
2022
Q4 		$15.1M Sell
381,451
-2,286
-0.6% -$95.4K 0.03% 617
2022
Q3 		$15.4M Buy
383,737
+47,070
+14% +$2.01M 0.03% 582
2022
Q2 		$14.2M Buy
336,667
+317,107
+1,621% +$13M 0.03% 634
2022
Q1 		$761K Buy
19,560
+11,980
+158% +$470K ﹤0.01% 2086
2021
Q4 		$301K Sell
7,580
-439
-5% -$17.1K ﹤0.01% 2606
2021
Q3 		$289K Buy
8,019
+6,924
+632% +$269K ﹤0.01% 2660
2021
Q2 		$44K Sell
1,095
-255
-19% -$10.8K ﹤0.01% 3140
2021
Q1 		$58K Sell
1,350
-134,555
-99% -$6.38M ﹤0.01% 3024
2020
Q4 		$6.8M Buy
135,905
+132,444
+3,827% +$5.62M 0.01% 1073
2020
Q3 		$145K Buy
+3,461
New +$148K ﹤0.01% 2896

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Russell Investments Group's RPRX Position: Q2 2026 in Review

Russell Investments Group increased its Royalty Pharma (RPRX) stake by 21% in Q2 2026, buying an estimated $15.4M and bringing the position to 1,694,250 shares worth $95.6M. The position accounts for 0.08% of the portfolio, ranked #236.

Russell Investments Group first reported a position in RPRX in Q3 2020 and has held it in 24 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Russell Investments Group held 1,694,250 shares of Royalty Pharma worth $95.6M as of Q2 2026.
  • Russell Investments Group bought 296,292 Royalty Pharma shares in Q2 2026, an estimated $15.4M.
  • Royalty Pharma made up 0.08% of Russell Investments Group's portfolio in Q2 2026, its #236 holding.
  • Russell Investments Group first reported a position in Royalty Pharma in Q3 2020 and has held it in 24 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.